Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer

Alexander Guimaraes, Shahin Tabatabei, Douglas Dahl, W. Scott McDougal, Ralph Weissleder, Mukesh G. Harisinghani

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: To assess lymphotrophic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with renal neoplasms. Methods: MRI was performed in 9 patients with renal masses. All patients were imaged on a GE 1.5T system with phased array body coil. Protocols included T2 and T2* weighted imaging before and after administration of ferumoxtran-10 (Combidex) for the evaluation of lymph node (LN) involvement. All 9 patients underwent nephrectomy. Lymph node dissection (LND) was performed in patients with stage 2 renal cell cancer (RCC), or transitional cell cancer (TCC), per routine clinical practice. Data analysis was performed by 2 radiologists, who were blinded to pathologic results. Nodes that lacked contrast uptake were deemed malignant, and those with homogeneous uptake were deemed benign. Quantitative, retrospective analysis was performed on primary tumors by quantifying T2* with a monoexponential fitting algorithm (Osirix). T2* was quantified before, immediately after, and 24 hours after the administration of ferumoxtran-10. Results: MRI demonstrated 26 lymph nodes within the 9 patients imaged (24 benign and 2 malignant). Pathologic results allowed comparison in 22 of the 26 lymph nodes and demonstrated high sensitivity (100%) and specificity (95.7%). Conclusions: LNMRI demonstrated high sensitivity (100%) and specificity (95.7%) in patients with renal neoplasms. Although in a relatively small sample size, the results are encouraging and warrant a larger, prospective trial.

Original languageEnglish (US)
Pages (from-to)708-712
Number of pages5
JournalUrology
Volume71
Issue number4
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Nanoparticles
Lymph Nodes
Magnetic Resonance Imaging
Kidney Neoplasms
Sensitivity and Specificity
Lymph Node Excision
Nephrectomy
Sample Size
Neoplasms
Kidney
ferumoxtran-10

ASJC Scopus subject areas

  • Urology

Cite this

Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer. / Guimaraes, Alexander; Tabatabei, Shahin; Dahl, Douglas; McDougal, W. Scott; Weissleder, Ralph; Harisinghani, Mukesh G.

In: Urology, Vol. 71, No. 4, 04.2008, p. 708-712.

Research output: Contribution to journalArticle

Guimaraes, Alexander ; Tabatabei, Shahin ; Dahl, Douglas ; McDougal, W. Scott ; Weissleder, Ralph ; Harisinghani, Mukesh G. / Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer. In: Urology. 2008 ; Vol. 71, No. 4. pp. 708-712.
@article{a9522dc3729c418b8368a81c1479ea61,
title = "Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer",
abstract = "Objective: To assess lymphotrophic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with renal neoplasms. Methods: MRI was performed in 9 patients with renal masses. All patients were imaged on a GE 1.5T system with phased array body coil. Protocols included T2 and T2* weighted imaging before and after administration of ferumoxtran-10 (Combidex) for the evaluation of lymph node (LN) involvement. All 9 patients underwent nephrectomy. Lymph node dissection (LND) was performed in patients with stage 2 renal cell cancer (RCC), or transitional cell cancer (TCC), per routine clinical practice. Data analysis was performed by 2 radiologists, who were blinded to pathologic results. Nodes that lacked contrast uptake were deemed malignant, and those with homogeneous uptake were deemed benign. Quantitative, retrospective analysis was performed on primary tumors by quantifying T2* with a monoexponential fitting algorithm (Osirix). T2* was quantified before, immediately after, and 24 hours after the administration of ferumoxtran-10. Results: MRI demonstrated 26 lymph nodes within the 9 patients imaged (24 benign and 2 malignant). Pathologic results allowed comparison in 22 of the 26 lymph nodes and demonstrated high sensitivity (100{\%}) and specificity (95.7{\%}). Conclusions: LNMRI demonstrated high sensitivity (100{\%}) and specificity (95.7{\%}) in patients with renal neoplasms. Although in a relatively small sample size, the results are encouraging and warrant a larger, prospective trial.",
author = "Alexander Guimaraes and Shahin Tabatabei and Douglas Dahl and McDougal, {W. Scott} and Ralph Weissleder and Harisinghani, {Mukesh G.}",
year = "2008",
month = "4",
doi = "10.1016/j.urology.2007.11.096",
language = "English (US)",
volume = "71",
pages = "708--712",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Pilot Study Evaluating Use of Lymphotrophic Nanoparticle-Enhanced Magnetic Resonance Imaging for Assessing Lymph Nodes in Renal Cell Cancer

AU - Guimaraes, Alexander

AU - Tabatabei, Shahin

AU - Dahl, Douglas

AU - McDougal, W. Scott

AU - Weissleder, Ralph

AU - Harisinghani, Mukesh G.

PY - 2008/4

Y1 - 2008/4

N2 - Objective: To assess lymphotrophic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with renal neoplasms. Methods: MRI was performed in 9 patients with renal masses. All patients were imaged on a GE 1.5T system with phased array body coil. Protocols included T2 and T2* weighted imaging before and after administration of ferumoxtran-10 (Combidex) for the evaluation of lymph node (LN) involvement. All 9 patients underwent nephrectomy. Lymph node dissection (LND) was performed in patients with stage 2 renal cell cancer (RCC), or transitional cell cancer (TCC), per routine clinical practice. Data analysis was performed by 2 radiologists, who were blinded to pathologic results. Nodes that lacked contrast uptake were deemed malignant, and those with homogeneous uptake were deemed benign. Quantitative, retrospective analysis was performed on primary tumors by quantifying T2* with a monoexponential fitting algorithm (Osirix). T2* was quantified before, immediately after, and 24 hours after the administration of ferumoxtran-10. Results: MRI demonstrated 26 lymph nodes within the 9 patients imaged (24 benign and 2 malignant). Pathologic results allowed comparison in 22 of the 26 lymph nodes and demonstrated high sensitivity (100%) and specificity (95.7%). Conclusions: LNMRI demonstrated high sensitivity (100%) and specificity (95.7%) in patients with renal neoplasms. Although in a relatively small sample size, the results are encouraging and warrant a larger, prospective trial.

AB - Objective: To assess lymphotrophic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with renal neoplasms. Methods: MRI was performed in 9 patients with renal masses. All patients were imaged on a GE 1.5T system with phased array body coil. Protocols included T2 and T2* weighted imaging before and after administration of ferumoxtran-10 (Combidex) for the evaluation of lymph node (LN) involvement. All 9 patients underwent nephrectomy. Lymph node dissection (LND) was performed in patients with stage 2 renal cell cancer (RCC), or transitional cell cancer (TCC), per routine clinical practice. Data analysis was performed by 2 radiologists, who were blinded to pathologic results. Nodes that lacked contrast uptake were deemed malignant, and those with homogeneous uptake were deemed benign. Quantitative, retrospective analysis was performed on primary tumors by quantifying T2* with a monoexponential fitting algorithm (Osirix). T2* was quantified before, immediately after, and 24 hours after the administration of ferumoxtran-10. Results: MRI demonstrated 26 lymph nodes within the 9 patients imaged (24 benign and 2 malignant). Pathologic results allowed comparison in 22 of the 26 lymph nodes and demonstrated high sensitivity (100%) and specificity (95.7%). Conclusions: LNMRI demonstrated high sensitivity (100%) and specificity (95.7%) in patients with renal neoplasms. Although in a relatively small sample size, the results are encouraging and warrant a larger, prospective trial.

UR - http://www.scopus.com/inward/record.url?scp=41149137543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149137543&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2007.11.096

DO - 10.1016/j.urology.2007.11.096

M3 - Article

VL - 71

SP - 708

EP - 712

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -